Aromatase inhibitors-induced osteoporosis

作者：Hadji P^*

来源：Osteologie, 2010, 19(2): 144-148.

• Breast cancer
• osteoporosis
• aromatase inhibitor
• fracture
• estradiol

Breast cancer and osteoporosis are two of the most frequent diseases leading to a decrease in life expectancy and the quality of life. In relation to this, estradiol plays a key role in the regulation of bone turnover as well as in the pathophysiology of breast cancer. During the first decade after the onset of menopause, the reduction of endogenous estradiol leads to a significant decrease in bone mass. Even in the elderly, very low levels of endogenous estradiol levels still play an important role in the maintenance of bone health. In the adjuvant endocrine treatment of postmenopausal breast cancer, tamoxifen has proven to have a protective effect on bone. In recent years, the use of aromatase inhibitors (AI) has significantly increased because of their superior effectiveness with regard to breast cancer outcomes. Unfortunately, in addition to other side effects, a decrease in bone mineral density and an increase in fracture risk were also shown as side effects.. This paper will provide a comprehensive review of the current knowledge with regard to the fracture incidence due to the use of different AIs as well as the prevention and treatment strategies for aromatase-induced bone loss.

• 出版日期2010